Brief Overview of Acute Myeloid Leukemia Acute myeloid leukemia (AML) is a heterogeneous clonal disease of myeloid-stem and progenitor cells resulting from mutations, deletions, and epigenetic alterations in genes associated with cell differentiation, proliferation, and renewal. AML represents roughly 1%…
Introduction Acute myeloid leukemia (AML) is the commonest indication for allogeneic hematopoietic cell transplant (allo-HCT) worldwide with numbers rising since its inception 65 years ago. The majority of patients with AML enter complete (morphologic) remission (CR1) with induction therapy; however,…
Introduction Radiation therapy is an effective treatment for many hematologic malignancies in a variety of contexts. In this chapter, we provide a brief review of the mechanism of external beam radiation, discuss radiobiologic principles that guide radiation response and fractionation,…
Introduction Medications used for hematopoietic cell transplant (HCT) and immune effector cell (IEC) therapies are often complex and carry numerous clinical considerations, including understanding of pharmacokinetic and pharmacodynamic principles, drug-drug interactions, adverse effects, and dose adjustment for organ dysfunction. This…
Hematopoietic Cell Transplant Preparative Regimens Goals of the Preparative Regimen Hematopoietic cell transplant (HCT) is a therapy that has the potential to cure or prolong the life of patients with hematologic malignancies as well as certain solid tumors and nonmalignant…
Introduction The introduction of chimeric antigen receptor (CAR) T-cell therapies represents the culmination of a decades-long journey to harness the immune system and exploit the antitumoral potential of immune cells to treat cancer. The first clinical experiences describing the administration…
Introduction The first successful cord blood transplantation (CBT) was performed by Dr. Gluckman, Dr. Broxmeyer, and their colleagues for a patient with Fanconi anemia in 1989. Since then, the application of CBT has broadened to include both malignant and nonmalignant…
Introduction Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment for various hematologic and immunologic disorders. Historically, selection of a suitable allo-HCT donor relied exclusively on degree of human leukocyte antigen (HLA) matching between the donor and the recipient to…
Blood products are essential during the peritransplant period. Patients receiving hematopoietic cell transplantation (HCT) require extensive transfusion support until appropriate platelet and red blood cell (RBC) engraftment ensures. The platelet lineage is considered engrafted when a patient’s platelet count is…
Introduction Hematopoietic cell transplantation (HCT) remains an essential therapeutic intervention for several high-risk hematologic neoplasms. HCT leads to durable responses and remissions for plasma cell neoplasms and indolent lymphomas and can be curative for aggressive lymphomas, acute leukemias, myelodysplastic syndromes,…